Liver fibrosis screening using simple blood tests in primary care
Part of Digestive system clinical trials.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old
- Your FIB-4 blood test result must be 2.67 or higher
- You must be covered by the Health Insurance System
- You can't have seen a liver or cancer specialist for this test order
- You can't have very high liver enzymes or very abnormal platelet counts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a city-hospital partnership can help find liver fibrosis (early scarring of the liver) earlier in people who get a Fibroscan test ordered by their primary care doctor. It is for adults whose Fibroscan result was at least 8 kPa and who had the test between 2023 and 2026.
This study is testing a new way to use a FibroScan (a non-invasive liver scanner) with a single probe to measure liver health in people with chronic liver disease. If you have a long-term liver condition, this trial may help improve how liver exams are done.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests a simple blood test (FIB-4) to check for liver scarring in people with type 2 diabetes. It may help find liver problems early so you can get the right care.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study uses a simple blood test to look for tiny particles from liver cells. It includes healthy volunteers, people with type 2 diabetes and liver scarring, and people with different stages of liver disease.
Hear when a new Hepatic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.